A Massachusetts enforcement action accusing subprime mortgage lender Fremont Investment & Loan of predatory lending was removed to the U.S. District Court for the District of Massachusetts on Tuesday.
Life sciences company Invitrogen Corp. has won the go-ahead to commence limited discovery in a lawsuit that accuses Harvard College's top guardians of wrongly laying claim to a molecular cloning patent.
In a boost to International Business Machines Corp., a federal judge has dismissed claims by a group of former employees that they were fired on the basis of their age, but has given the plaintiffs leave to amend their complaint.
A purported class of FedEx Ground Package System Inc. drivers has asked an Indiana district court to block the delivery company's plan to end its contractor employee model in California, claiming the move is being done in retaliation for the suit.
A Washington-based software provider has rounded up Fanuc Ltd. and several GE subsidiaries in a patent infringement suit over integrated technology for robotic machines.
As the battle rages on between California and the U.S. Environmental Protection Agency over the regulation of greenhouse gas emissions from automobiles, legal experts are at odds over how much of a role last month's ruling in a related Vermont case will play in the upcoming decision.
In a landmark ruling, a Vermont district judge has knocked down top auto makers' attempts to derail a state's efforts to significantly curb carbon dioxide emissions from cars and light trucks, handing environmental groups another big win in their crusade against global warming.
Citing concerns over Microsoft's still dominant position in the software market, California and six other states asked a federal judge on Tuesday to extend antitrust oversight of the software giant to 2012, five years past the original Nov. 12 expiration date.
The Department of Justice declared victory on Thursday in its antitrust enforcement efforts against Microsoft. But a group of state attorneys general were less enthusiastic about the agency’s assessment.
Abbott Laboratories Inc. has lashed out at a judge's order allowing a plaintiff in the average wholesale price litigation to share discovery from other state cases against the drug maker with government prosecutors, arguing that the information has “nothing to do with the claims” in the multidistrict action.
A day after a key U.S. Senate panel voted to give the U.S. Food and Drug Administration more power to regulate tobacco, the California Supreme Court has sided against a pack of smokers that accused a handful of tobacco giants of attempting to target children with misleading cigarette advertisements.
Abbott Laboratories, one of a slew of pharmaceutical makers involved in a massive antitrust class action alleging the companies defrauded consumers by artificially inflating the prices for various prescription drugs, has moved to dismiss fresh claims brought by government authorities.
Two U.S. Senators have introduced a bill that would force the U.S. Environmental Protection Agency to decide on California's request to regulate greenhouse gas emissions by Sept. 30.
The U.S. Environmental Protection Agency issue a decision by the end of the year over whether California should be granted a waiver allowing it to impose greenhouse gas emission reductions, it said in a letter to Gov. Arnold Schwarzenegger.
The former co-chair of Morrison & Foerster LLP's antitrust group has left for a smaller firm, citing the challenge of building a group and the desire to take interesting cases with less regard for the bottom line.
Bristol-Myers Squibb Co. has filed a slew of motions to exclude certain evidence from being presented at an upcoming jury trial over allegations that it and other major pharmaceutical companies inflated average wholesale drug prices.
As the battle over how best to regulate the reduction of greenhouse gas emissions heats up, lawmakers on Thursday indicated their intention to try to block a congressional energy plan that would limit states' regulatory powers on the issue.
Drug maker Abbott Laboratories inflated its published pharmaceutical prices by up to 1000% to scam Medicare and boost sales of its drugs, U.S. health officials claimed in a lawsuit.
Abbott Laboratories has accused California health authorities in a Medicare fraud case of “inflammatory rhetoric,” arguing the allegations against it were barred by the government's own negligence.
The state of California on Wednesday voluntarily dismissed claims against Bristol-Myers Squibb Co. accusing the health care giant of inflating average wholesale drug prices.